Inovio Pharmaceuticals (INO) volatility flat into U.S. FDA placed a clinical hold proposed phase III clinical program for VGX-3100.

October 24, 2016 9:18 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Inovio Pharma (NASDAQ: INO) October put option implied volatility is at 66, January is at 64; compared to its 52-week range of 48 to 114 into the U.S. FDA placed a clinical hold on its proposed phase III clinical program for VGX-3100.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options

Add Your Comment